Vertex Pharmaceuticals Incorporated (VX1.F)
| Previous close | 449.65 |
| Open | 440.65 |
| Bid | 440.75 x 10000 |
| Ask | 442.20 x 10000 |
| Day's range | 440.65 - 442.75 |
| 52-week range | 307.15 - 450.70 |
| Volume | |
| Avg. volume | 49 |
| Market cap | 114.253B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 30.77 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON, June 14, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved CRI
- Business Wire
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON, June 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland.
- Business Wire
Vertex to Participate in Upcoming June Investor Conferences
BOSTON, May 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
